Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model

Clinical and Experimental Metastasis

Volumn 20, Issue 5, 2003, Pages 407-412

  Nozaki, Shinichi ^a,b   Sissons, Sean ^a   Chien, Du Shieng ^c   Sledge Jr , George W ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c BAYER CORPORATION   (United States)

Author keywords

Angiogenesis; Breast cancer; Matrix metalloproteinase inhibitor; Orthotopic transplant model; Pulmonary metastasis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; TANOMASTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; XENOGRAFT; ZYMOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; ORGANIC CHEMICALS; TIME FACTORS; TUMOR CELLS, CULTURED; UMBILICAL VEINS;

EID: 0043238937     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025473709656     Document Type: Article

References (17)

1. Liotta LA. Tumor invasion and metastasis: role of the extracellular matrix. Cancer Res 1986; 46: 1-7.
2. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
3. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-70.
4. Fidler LJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 85-8.
5. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Exp Opin Invest Drugs 2000; 9: 2167-77.
6. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002; 2: 657-72.
7. Hibner B, Card A, Flynn C et al. BAY 12-9566, a novel, biphenyl matrix metalloproteinase inhibitor, demonstrates anti-invasive and anti-angiogenic properties. Proc Am Assoc Cancer Res 1998; 39: 302.
8. Bull C, Flynn C, Eberwein D et al. Activity of the biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in murine in vivo models. Proc Am Assoc Cancer Res 1998; 39: 302.
9. Flynn C, Bull C, Eberwein D et al. Anti-metastatic activity of BAY 12-9566 in a human colon carcinoma HCT116 orthotopic model. Proc Am Assoc Cancer Res 1998; 39: 301.
10. Nehls V, Drenckhahn D. A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis. Microvasc Res 1995; 50: 311-22.
11. Sweeney CJ, Miller KD, Sissons S et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61: 3369-72.
12. Sledge GW Jr, Qulali M, Goulet R et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995; 87: 1546-50.
13. Brown PD, Levy AT, Margulies IM et al. Independent expression and cellular processing of Mr 72 000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 1990; 50: 6184-91.
14. Nozaki S, Sledge GW Jr, Nakshatri H. Inhibitor-of-kB super-repressor inhibits growth and pulmonary metastasis of MDA-MB-435 breast cancer cells in nude mice. Proc Am Assoc Cancer Res 2000; 41: 382.
15. Grochow L, O'Reilly S, Humphrey R et al. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI), BAY 12-9566. Proc Am Soc Clin Oncol 1998; 17: 822.
16. Wojtowicz-Praga S, Low J, Marshall J et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 1996; 14: 193-202.
17. Yu AE, Hewitt RE, Connor EW et al. Matrix metalloproteinases. Novel targets for directed cancer therapy. Drug Aging 1997; 11: 229-44.